Cell Genesys News (NASDAQ:CEGE)
| Latest Cell Genesys News Headlines | | Date | Time | Source | | | 06/27/2008 | 10:00AM | PRNUS | BeaconEquity.com Issues TraderNotes on Active Stocks: SWHC, ARNA, BORL, QTWW, CSGH, FEED, BVN, CEGE
DALLAS, June 27 /PRNewswire/ -- BeaconEquity.com announces the availability of TraderNotes on stocks that are making news today.
Investors can view all of the daily trading notes for free by visiting:
http://www.beaconequity.com/m
Today's TraderNotes include: Smith & Wesson Holding Corp. (NASDAQ:SWHC), Arena... More...>> |
| 04/23/2008 | 7:00AM | PRNUS | Ceregene Announces Two Key Additions to Leadership Team
SAN DIEGO, April 23 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today announced that it has added two key people to its management team. Maurice Mezzino has been hired to the position of vice president, chief business officer, and Andrea Loewen-Rodriguez joins the company as senior director, regulatory... More...>> |
| 03/11/2008 | 8:30AM | PRNUS | Cell Genesys to Present at the Cowen and Company and the Lehman Brothers Healthcare Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE) today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update on Tuesday, March 18 at 8:00 a.m. ET at the Cowen and Company 28th Annual Healthcare... More...>> |
| 02/28/2008 | 4:00PM | PRNUS | Cell Genesys Reports Fourth Quarter and Year-End 2007 Results
Conference Call Scheduled for 5:00 p.m. ET Today
SOUTH SAN FRANCISCO, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE) today reported financial results for the fourth quarter and full year ended December 31, 2007. The company reported a net loss of $33.4 million ($0.43 per fully diluted share... More...>> |
| 02/21/2008 | 8:30AM | PRNUS | Cell Genesys to Webcast Fourth Quarter and Year-End 2007 Conference Call
SOUTH SAN FRANCISCO, Calif., Feb. 21 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will host a conference call relating to the company's... More...>> |
| 02/19/2008 | 9:49AM | PRNUS | BeaconEquity.com Issues TraderNotes on RMDX, CEGE, PCLN, BRCD, and CEM
DALLAS, Feb. 19 /PRNewswire/ -- BeaconEquity.com announces the availability of TraderNotes on stocks that are making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/
Today's TraderNotes include: RemoteMDx, Inc. (OTC:RMDX) (BULLETIN BOARD: RMDX) , Cell... More...>> |
| 02/15/2008 | 8:30AM | PRNUS | Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostat
SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE) today reports the results of an analysis examining the potential association between immune responses to GVAX immunotherapy for prostate cancer and increased patient survival in a Phase 2 trial in patients with metastatic... More...>> |
| 02/04/2008 | 8:30AM | PRNUS | Cell Genesys to Present at the BIO CEO and Investor Conference
SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the BIO CEO and Investor Conference in New York, New York, on Monday, February 11, 2008... More...>> |
| 01/14/2008 | 9:00AM | PRNUS | Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Conference Call Scheduled for 10:00 a.m. ET Today
SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE) today announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer... More...>> |
| 01/07/2008 | 7:00AM | PRNUS | Ceregene to Present at JPMorgan 26th Annual Healthcare Conference
SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Ceregene, Inc. today announced that Jeffrey M. Ostrove, Ph.D., president and chief executive officer, will present at the JPMorgan 26th Annual Healthcare Conference in San Francisco, CA on Thursday, January 10th at 11:30 a.m. PST.
"We look forward to participating in this... More...>> |
| 01/02/2008 | 8:30AM | PRNUS | Cell Genesys to Present at the 26th Annual JPMorgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 2 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the 26th Annual JPMorgan Healthcare Conference in San Francisco, California, on Wednesday... More...>> |
| 12/20/2007 | 2:21PM | PRNUS | Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million
SOUTH SAN FRANCISCO, Calif., and GREENWICH, Conn., Dec. 20 /PRNewswire- FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE) and GBP IP, LLC, an affiliate of GBP Capital, the majority shareholder in privately held Lentigen Corporation, today announced that the two companies have entered into an asset sale agreement relating... More...>> |
| 12/12/2007 | 7:00AM | PRNUS | Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease
Data Suggest Continued Improvement in Motor Function at 24 Months
SAN DIEGO, Dec. 12 /PRNewswire/ -- Ceregene, Inc. today presented long-term follow-up data from a Phase 1 clinical trial of CERE-120 in 12 patients with advanced Parkinson's disease. CERE-120 uses gene therapy to deliver the neural growth factor neurturin... More...>> |
| 12/06/2007 | 7:00AM | PRNUS | Ceregene Promotes Dr. Raymond Bartus to Executive Vice President
SAN DIEGO, Dec. 6 /PRNewswire/ -- Ceregene, Inc. today announced the promotion of Raymond T. Bartus, Ph.D., to the position of executive vice president of clinical and preclinical R&D and chief operating officer. Since joining Ceregene in 2002, Dr. Bartus has led the preclinical and clinical development efforts for... More...>> |
| 11/14/2007 | 7:00AM | PRNUS | Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease
SAN DIEGO, Nov. 14 /PRNewswire-FirstCall/ -- Ceregene, Inc. today announced that the company has completed enrollment of its randomized, controlled, double-blind, Phase 2 clinical trial evaluating CERE-120, a gene therapy product in development for the treatment of Parkinson's disease. The trial enrolled 58 patients... More...>> |
| 11/06/2007 | 8:30AM | PRNUS | Cell Genesys to Present at the JMP Securities Sector Focus Conference
SAN FRANCISCO, Nov. 6 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the JMP Securities Sector Focus Conference in Boston, Massachusetts on Tuesday, November 13, 2007, at... More...>> |
| 11/01/2007 | 4:00PM | PRNUS | Cell Genesys Reports Third Quarter 2007 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE) today reported financial results for the third quarter ended September 30, 2007. The company reported a net loss of $34.5 million, or $0.46 per fully diluted share, for the third quarter of 2007, compared with a net loss... More...>> |
| 10/30/2007 | 8:30AM | PRNUS | Cell Genesys to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE), today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update at the Rodman and Renshaw 9th Annual Healthcare Conference in New York City on Tuesday... More...>> |
| 10/25/2007 | 8:30AM | PRNUS | Cell Genesys to Webcast Third Quarter 2007 Conference Call
SOUTH SAN FRANCISCO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will host a conference call relating to the company's... More...>> |
| 10/03/2007 | 8:30AM | PRNUS | Cell Genesys to Present at the BIO Investor Forum
SOUTH SAN FRANCISCO, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (NASDAQ:CEGE), today announced that Robert Dow, MBChB, chief medical officer of Cell Genesys, will present a company update on Wednesday, October 10, at 10:15 a.m. PT at the BIO Investor Forum being held in San Francisco, California.
A... More...>> |
|
|
|